Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

Report Ocean, a leading strategic consulting and market research firm, in its recent study, estimated the Asia Pacific Lancet and Pen Needles Market size at USD 1,416.30 million in 2023. During the ...

Eli Lilly Takes on Novo Nordisk with Orforglipron, an Oral Drug for Diabetes and Obesity That Could Change the Market. FDA ...

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time.

After selling off a portion of its diabetes care business last year, Ypsomed is now fully exiting the diabetes care business ...

This all suggests that orforglipron is useful for both treating diabetes and weight loss -- and with no needles required ... bad news for investors in Novo Nordisk and Viking Therapeutics ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

In 2020, the US Food and Drug Administration approved Novo Nordisk ... needle-phobic,” said Dr. Amy Rothberg, a clinical professor of medicine in the Division of Metabolism, Endocrinology ...

Novo Nordisk A/S has moved -53.6% over the last year, and the S&P 500 logged a change of 5.4% NVO has an average analyst ...

T he US Food and Drug Administration (FDA) and pharmaceutical company Novo Nordisk are now in an attempt to making more ...